The Egyptian Drug Authority—represented by the Pharmacoeconomics Unit under the General Administration for Market Support and Business Continuity—announces the start of receiving files for medical products submitted for price assessment for the first time, where the lowest manufacturer selling price in the reference pricing countries' list falls within the price category from 50,000 Egyptian pounds to 500,000 Egyptian pounds. Consequently, the conditions for activating the value-based pricing mechanism apply in accordance with the Chairman of the Authority's Decree No. 480 of 2026 regarding the regulations and procedures for pricing human medical products.

1. Download the form specific to the requirements of the value-based pricing assessment procedure.

2. Fill out all sections of the form, ensuring that the required attachments are uploaded via the link mentioned in the form.

3. Attach the completed form within its respective parts on the automated pricing policies software among the product's price application attachments.

4. In case of any inquiries regarding this form, use the link.